ArticleMikrochimica acta2026
Hybrid plasmonic fiber optic sensor enabling rapid and amplification-free nucleic acid determination for disease screening.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A tilted fiber Bragg grating-surface plasmon resonance biosensing platform is reported for rapid, amplification-free determination of viral nucleic acids in complex clinical matrices. The transducer integrates Au nanoparticles, Ta2C-MXene, and an Au film into a hybrid plasmonic architecture that creates a stereoscopic refractive index sensing region through localized gap-plasmon coupling. Finite element modeling reveals that the three-dimensional electromagnetic field extends the effective sensing volume beyond the classical near-field limit. The field also generates strong gradients that induce dielectrophoretic forces. This mechanism actively enriches analytes at the sensing interface, thereby enhancing signal transduction. Experimentally, a co-immobilized hybrid DNA probe strategy was employed to improve the capture efficiency of long and structured viral sequences. The combination of the dual-probe recognition interface and the optimized plasmonic transducer enables direct, amplification-free determination of severe acute respiratory syndrome coronavirus 2 nucleic acids. Using nasopharyngeal swab samples, the platform achieves a limit of detection of 130 copies·µL–1. The average diagnostic time is approximately 61 s. The sensor exhibited agreement with qRT-PCR results across 30 clinical samples and retained high sensitivity in 10-in-1 pooled testing.
Indexed as
Identifiers
41622371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.